Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-RSV01 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-RSV01 | ACTIVE_COMPARATOR | - |
| Normal saline | PLACEBO_COMPARATOR | - |
| 1 | ACTIVE_COMPARATOR | ALN-RSV01 |
| 2 | PLACEBO_COMPARATOR | Normal saline |
| Name | Type | Description |
|---|---|---|
| ALN-RSV01 | DRUG | Administered by nebulization once daily for 5 days |
| Normal Saline | DRUG | Administered by nebulization once daily for 5 days |
Inclusion Criteria: * Single or bilateral lung transplant recipients * Confirmed RSV infection * Greater than 90 days post current lung transplant * Rejection free for a minimum of 30 days Exclusion Criteria: * Known viral, bacterial, or fungal respiratory co-infection at the time of RSV diagnosi...
ALN-RSV01 is an investigational drug being studied for the treatment of Respiratory Syncytial Virus (RSV) infections. It has been evaluated in clinical trials involving adult volunteers and lung transplant patients infected with RSV. The drug is administered intranasally and is currently in Phase 2 clinical development.
ALN-RSV01 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company has conducted multiple clinical trials to evaluate the safety and efficacy of ALN-RSV01 in patients with Respiratory Syncytial Virus infections.
ALN-RSV01 is in Phase 2 clinical development. It has completed three Phase 2 trials, including a Phase 2b study in lung transplant patients infected with Respiratory Syncytial Virus. The drug is investigational and has not been approved by regulatory authorities for commercial use.
ALN-RSV01 has been studied in three completed Phase 2 clinical trials. These include NCT00496821, a study in adult volunteers experimentally inoculated with RSV; NCT00658086, a Phase 2 study in lung transplant patients with RSV; and NCT01065935, a Phase 2b study in lung transplant patients with RSV. All trials have been completed.
ALN-RSV01 is a distinct investigational drug being developed specifically for Respiratory Syncytial Virus infections. It is not known to be the same as any other marketed RSV treatment. Its development is focused on evaluating its potential as a therapeutic option for RSV, particularly in lung transplant patients.